Impact of low-density lipoprotein cholesterol and lipoprotein(a) on mid-term clinical outcomes following coronary artery bypass grafting: a secondary analysis of the dacab trial

HIGHLIGHTS

• who: Qixiang Yu et al. from the hospitals were randomized to ticagrelor , mg twice daily plus aspirin , mg once daily, ticagrelor alone , mg twice daily, or aspirin alone , mg once daily for, year open-label antiplatelet therapy after CABG between July , and November The primary outcome was, year vein graft patency at the graft level. The trial design and eligibility criteria have been published previously (18). In this secondary analysis, patients who had LDL-C and Lp(a) measured at baseline and LDL-C repeatedly measured during the follow-up period were pooled. Thus, patients in the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.